Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease
OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colch...
Gespeichert in:
Veröffentlicht in: | The Annals of pharmacotherapy 2004-05, Vol.38 (5), p.808-811 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 811 |
---|---|
container_issue | 5 |
container_start_page | 808 |
container_title | The Annals of pharmacotherapy |
container_volume | 38 |
creator | Sayarlioglu, Mehmet Kotan, Mehmet Cetin Topcu, Nazan Bayram, Irfan Arslanturk, Hasan Gul, Ahmet |
description | OBJECTIVE
To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD).
CASE SUMMARY
A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months.
DISCUSSION
The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration.
CONCLUSIONS
Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy. |
doi_str_mv | 10.1345/aph.1D524 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71838851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1D524</sage_id><sourcerecordid>71838851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</originalsourceid><addsrcrecordid>eNptkMtOwzAQRS0E4lFY8APIG0AsUsax3ThLaHlJSCBUFqwsN5k0RnkUO1HE3-PSSmxYzR3p6M7oEHLKYMy4kNdmVY7ZTMZihxwyKeJoEiewGzJMIIJYwQE58v4TAFIWp_vkgElgIGN-SD7mDk1XY9PRtqBvmPXOrZdXdEXrTGebJX1qOvQhmYq-Vxk6TwfblXRemsrmbW1zpLaht1hm2F16OrMejcdjsleYyuPJdo7I-_3dfPoYPb88PE1vnqOMT5IuMgUkEgVkUsICpOBCGZEznkuu0gU3qZJK4UQtRJKkhTIyLbgwkKVpHlAh-IhcbHpXrv3qw6O6tj7DqjINtr3XCVNcKckCeLUBM9d677DQK2dr4741A732qINH_esxsGfb0n5RY_5HbsX9XfVmifqz7V3Q4_9tOt-ApV2Wg3WofW2qKvQyPQwDV1pqBYr_AJephoo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71838851</pqid></control><display><type>article</type><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</creator><creatorcontrib>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</creatorcontrib><description>OBJECTIVE
To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD).
CASE SUMMARY
A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months.
DISCUSSION
The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration.
CONCLUSIONS
Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1D524</identifier><identifier>PMID: 15010523</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adult ; Behcet Syndrome - drug therapy ; Female ; Humans ; Intestinal Perforation - drug therapy ; Recurrence ; Thalidomide - therapeutic use</subject><ispartof>The Annals of pharmacotherapy, 2004-05, Vol.38 (5), p.808-811</ispartof><rights>2004 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</citedby><cites>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1D524$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1D524$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15010523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sayarlioglu, Mehmet</creatorcontrib><creatorcontrib>Kotan, Mehmet Cetin</creatorcontrib><creatorcontrib>Topcu, Nazan</creatorcontrib><creatorcontrib>Bayram, Irfan</creatorcontrib><creatorcontrib>Arslanturk, Hasan</creatorcontrib><creatorcontrib>Gul, Ahmet</creatorcontrib><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE
To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD).
CASE SUMMARY
A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months.
DISCUSSION
The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration.
CONCLUSIONS
Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adult</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Intestinal Perforation - drug therapy</subject><subject>Recurrence</subject><subject>Thalidomide - therapeutic use</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtOwzAQRS0E4lFY8APIG0AsUsax3ThLaHlJSCBUFqwsN5k0RnkUO1HE3-PSSmxYzR3p6M7oEHLKYMy4kNdmVY7ZTMZihxwyKeJoEiewGzJMIIJYwQE58v4TAFIWp_vkgElgIGN-SD7mDk1XY9PRtqBvmPXOrZdXdEXrTGebJX1qOvQhmYq-Vxk6TwfblXRemsrmbW1zpLaht1hm2F16OrMejcdjsleYyuPJdo7I-_3dfPoYPb88PE1vnqOMT5IuMgUkEgVkUsICpOBCGZEznkuu0gU3qZJK4UQtRJKkhTIyLbgwkKVpHlAh-IhcbHpXrv3qw6O6tj7DqjINtr3XCVNcKckCeLUBM9d677DQK2dr4741A732qINH_esxsGfb0n5RY_5HbsX9XfVmifqz7V3Q4_9tOt-ApV2Wg3WofW2qKvQyPQwDV1pqBYr_AJephoo</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Sayarlioglu, Mehmet</creator><creator>Kotan, Mehmet Cetin</creator><creator>Topcu, Nazan</creator><creator>Bayram, Irfan</creator><creator>Arslanturk, Hasan</creator><creator>Gul, Ahmet</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><author>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adult</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Intestinal Perforation - drug therapy</topic><topic>Recurrence</topic><topic>Thalidomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sayarlioglu, Mehmet</creatorcontrib><creatorcontrib>Kotan, Mehmet Cetin</creatorcontrib><creatorcontrib>Topcu, Nazan</creatorcontrib><creatorcontrib>Bayram, Irfan</creatorcontrib><creatorcontrib>Arslanturk, Hasan</creatorcontrib><creatorcontrib>Gul, Ahmet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sayarlioglu, Mehmet</au><au>Kotan, Mehmet Cetin</au><au>Topcu, Nazan</au><au>Bayram, Irfan</au><au>Arslanturk, Hasan</au><au>Gul, Ahmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>38</volume><issue>5</issue><spage>808</spage><epage>811</epage><pages>808-811</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><abstract>OBJECTIVE
To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD).
CASE SUMMARY
A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months.
DISCUSSION
The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration.
CONCLUSIONS
Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>15010523</pmid><doi>10.1345/aph.1D524</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1060-0280 |
ispartof | The Annals of pharmacotherapy, 2004-05, Vol.38 (5), p.808-811 |
issn | 1060-0280 1542-6270 |
language | eng |
recordid | cdi_proquest_miscellaneous_71838851 |
source | MEDLINE; SAGE Complete |
subjects | Adjuvants, Immunologic - therapeutic use Adult Behcet Syndrome - drug therapy Female Humans Intestinal Perforation - drug therapy Recurrence Thalidomide - therapeutic use |
title | Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A45%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Recurrent%20Perforating%20Intestinal%20Ulcers%20with%20Thalidomide%20in%20Behcet's%20Disease&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Sayarlioglu,%20Mehmet&rft.date=2004-05-01&rft.volume=38&rft.issue=5&rft.spage=808&rft.epage=811&rft.pages=808-811&rft.issn=1060-0280&rft.eissn=1542-6270&rft_id=info:doi/10.1345/aph.1D524&rft_dat=%3Cproquest_cross%3E71838851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71838851&rft_id=info:pmid/15010523&rft_sage_id=10.1345_aph.1D524&rfr_iscdi=true |